These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30730272)

  • 41. Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression.
    Curdy N; Lanvin O; Laurent C; Fournié JJ; Franchini DM
    Trends Cell Biol; 2019 Oct; 29(10):777-790. PubMed ID: 31378317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.
    Zhang Y; Chen L
    JAMA Oncol; 2016 Nov; 2(11):1403-1404. PubMed ID: 27490017
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 45. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
    Lim AR; Rathmell WK; Rathmell JC
    Elife; 2020 May; 9():. PubMed ID: 32367803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PTEN loss correlates with T cell exclusion across human cancers.
    Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
    BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
    RodrÍguez E; Schetters STT; van Kooyk Y
    Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
    Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
    [No Abstract]   [Full Text] [Related]  

  • 50. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tissue Site and the Cancer Immunity Cycle.
    Horton BL; Fessenden TB; Spranger S
    Trends Cancer; 2019 Oct; 5(10):593-603. PubMed ID: 31706507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumoural immunotherapies in oncology.
    Xu W; Atkinson VG; Menzies AM
    Eur J Cancer; 2020 Mar; 127():1-11. PubMed ID: 31962197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
    Overwijk WW
    Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
    Ellmark P; Mangsbo SM; Furebring C; Norlén P; Tötterman TH
    Cancer Immunol Immunother; 2017 Jan; 66(1):1-7. PubMed ID: 27714433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
    Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
    Front Immunol; 2021; 12():645242. PubMed ID: 33815400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.
    Seliger B
    Front Immunol; 2019; 10():2043. PubMed ID: 31555274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
    Ho PC; Kaech SM
    Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
    Corrales L; Gajewski TF
    Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
    [No Abstract]   [Full Text] [Related]  

  • 59. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 60. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
    Leone RD; Powell JD
    Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.